Abstract | The rising global prevalence of diabetes mellitus is accompanied by an increasing burden of morbidity and mortality that is attributable to the complications of chronic hyperglycaemia. These complications include blindness, renal failure and cardiovascular disease. Current therapeutic options for chronic hyperglycaemia reduce, but do not eradicate, the risk of these complications. Success in defining new preventative and therapeutic strategies hinges on an improved understanding of the molecular processes involved in the development of these complications. This Review explores the role of human genetics in delivering such insights, and describes progress in characterizing the sequence variants that influence individual predisposition to diabetic kidney disease, retinopathy, neuropathy and accelerated cardiovascular disease. Numerous risk variants for microvascular complications of diabetes have been reported, but very few have shown robust replication. Furthermore, only limited evidence exists of a difference in the repertoire of risk variants influencing macrovascular disease between those with and those without diabetes. Here, we outline the challenges associated with the genetic analysis of diabetic complications and highlight ongoing efforts to deliver biological insights that can drive translational benefits.
Introduction
Diabetes mellitus is associated with a range of microvascular, macrovascular and metabolic complications, which together have a sizeable and increasing impact on the global burden of morbidity and mortality. 1, 2 Diabetes is the leading global cause of end-stage renal disease (ESRD), and a major contributor to blindness, lower limb amputation, and cardiac disease. 3, 4 Despite substantial research efforts, there remains considerable uncertainty over the underlying mechanisms whereby prolonged hyperglycaemia, in concert with the other metabolic features of diabetes, results in such a characteristic pattern of damage. Although the pathology and epidemiology of diabetic kidney disease (DKD) are well described, 5 in particular for type 1 diabetes mellitus (T1DM), 5 the processes underlying its development and the factors that influence individual predisposition are poorly understood. 6 The extent to which the mechanisms underlying DKD among patients with T1DM or type 2 diabetes mellitus (T2DM) are shared is a matter of debate: whereas the overall clinical presentation is similar for both T1DM and T2DM, the histological findings in T2DM are notably more variable as compared with T1DM. This difference in part reflects the comorbidity and age-associated effects of hypertension and coexisting atherosclerosis. [7] [8] [9] [10] The degree to which florid cardiovascular disease in patients with poorly controlled diabetes reflects qualitatively distinct processes, rather than acceleration of the mechanisms that operate in normoglycaemic individuals, is also far from clear. Uncertainties over the causal mechanisms under lying diabetic complications represent serious obstacles to the development of strategies to address currently unmet medical needs, impeding efforts to identify validated therapeutic targets that can be subsequently modulated for remedial benefit. These challenges are illustrated by aliskiren, a direct inhibitor of renin. Despite considerable prior data indicating that this drug would be a useful adjunct in the management of DKD, the data obtained from clinical trials suggested otherwise. 11 The ALTITUDE study found no significant difference in renal and cardiovascular outcomes between patients treated with aliskiren and those who received placebo. 11 Absence of a definitive mechanistic framework for disease pathogenesis further limits the capacity to stratify individual risk, for example, through the use of surrogate biomarkers to monitor the development and progression of diabetic complications. The absence of a mechanistic framework also negatively influences individual clinical management and contributes to the excessive costs associated with developing novel therapies. 12, 13 The identification of robust surrogate biomarkers for DKD, approved by the relevant regulatory authorities, enable clinical trials to be more efficient and involve smaller numbers of patients at high risk of complications (selected on the basis of genetic or non-genetic biomarker status) to be followed for shorter intervals than would otherwise be the case for clinical trials of renal outcomes. disease, diabetic retinopathy, diabetic neuropathy and DKD. Compelling evidence has indicated that individual predisposition to DKD in patients with T1DM has a substantial genetic component. [15] [16] [17] [18] [19] [20] [21] [22] Identification of the specific genetic variants responsible for such predisposition offers a powerful strategy to define key pathogenetic mechanisms and generate therapeutic targets with a causal link to human disease. In addition, characterization of the wider phenotypic impact of a variant of interest provides clues to the potential consequences of therapeutic perturbation of the cognate pathwayinformation that can help to prioritize among a set of potential therapeutic targets. 23 
Microvascular complications
Diabetic kidney disease DKD affects ~30% of all patients with T1DM or T2DM. 24, 25 The early phase of DKD is typically characterized by glomerular hyperfiltration, followed by progressive morphological and ultrastructural changes, including expansion of the extracellular matrix (ECM) and loss of the charge barrier in the glomerular basement membrane. 26 The overall result of such changes is protein leakage, characterized initially as microalbuminuria (urinary albumin excretion rate [AER] 20-199 μg/min) that progresses to macroalbuminuria (AER ≥200 μg/min). The estimated glomerular filtration rate (eGFR) decreases, leading to chronic kidney disease (CKD; eGFR <60 ml/min/1.73 m 2 ) and subsequent ESRD (eGFR <15 ml/min/1.73 m 2 ). This sequence of events is, however, not evident in every patient. Regression to normoalbuminuria is common in the early stages of DKD, and DKD can progress to ESRD in the absence of severe albuminuria. 27, 28 The pathological processes involved in DKD are complex and only partly known. High glucose concentrations are central to the development and progression of DKD, affecting various cell types including endo thelial and mesangial kidney cells, podocytes and inflammatory cells, as well as the renal tubular and collecting duct systems. Multiple pathways are probably involved. Increases in the mitochondrial generation of reactive oxygen species (ROS) and in the cellular expression of TGF-β, are important consequences of hyperglycaemia.
Key points
■ The majority of the morbidity and mortality associated with diabetes mellitus is due to complications, such as diabetic kidney disease ■ A limited understanding of the underlying mechanisms responsible for the development of diabetic complications compromises efforts to develop novel strategies for treatment and prevention ■ Studies of human genetics offer powerful tools for delivering robust mechanistic insights into complex traits, such as diabetic complications, which have a substantial genetic component ■ Scientific progress to date has been limited by small sample sizes and/or phenotypic imprecision; however, several major discovery efforts are underway that have been designed to address these issues ■ The identification of genetic variants with robust effects on the risk of developing diabetic complications will accelerate efforts to develop more effective strategies for treatment and prevention ROS activate signalling molecules and transcription factors, leading to increased expression of cytokines, growth factors, and ECM proteins, macrophage infiltration and overproduction of leucocyte adhesion molecules in the kidneys. TGF-β also stimulates ECM generation, contributing to cellular hypertrophy and enhanced collagen synthesis. 6 Individual risk of DKD is markedly influenced by genetic predisposition. Evidence for a genetic component comes from pedigree studies showing familial aggregation of DKD in both T1DM and T2DM, and from what seem to be robust differences in prevalence among various ethnic groups. [15] [16] [17] [18] 22, 29 The estimated heritability of AER is ~20-40% and diabetic siblings of patients with DKD have a twofold increased risk of also developing DKD. [30] [31] [32] [33] Several studies have demonstrated that non-diabetic parents of individuals with T1DM and DKD are more likely than expected to be hypertensive, or to suffer from cardiovascular disease. [19] [20] [21] These data indicate that predisposition to DKD is likely to be conveyed through genetic variants that influence cardiovascular function.
Despite compelling evidence for genetic effects, the search for specific variants that confer predisposition to DKD has been relatively unrewarding, especially when progress is compared with that for other complex traits. Key factors that compromise the ability to detect robust genotype-phenotype associations include phenotypic imprecision 34 and inadequate sample sizes. 35 DKD is a progressive condition that typically develops >15 years after the onset of diabetes; this late onset limits access to patients (especially those with T2DM) with sufficient duration of disease for reliable assignment of case-control status. To increase sample sizes, many studies have included individuals with DKD defined by the presence of either albuminuria or ESRD; however, albumin uria is a poor predictor of DKD, especially in the early stages of presentation, adding further uncertainty to the classification of DKD. 28, 36 Reduced kidney function (revealed by eGFR and ESRD) and dysfunction of the glomerular filtration barrier (reflected by albuminuria) can develop independently of each other, suggesting that these pathologies result in part from different disease mechanisms with distinct genetic determinants. 27, 28, 37, 38 Empirical support for this view comes from an analysis of the relative proportions of risk alleles and low-frequency alleles for the DKD phenotype. 39 Consequences of this mechanistic hetero geneity include decreased power to identify risk variants, as well as the prospect that true findings might prove difficult to replicate because of subtle phenotypic differences between study samples. These issues are compounded in studies of DKD among patients with T2DM, in whom an observed decline in renal function might be either wholly or in part due to the consequence of other pathologies driven by hypertension or renal atheroma. Indeed, a rather low proportion of patients with T2DM (one study reported 36%) 40 who present with renal disease have histological features of classical DKD when biopsy material is available. 41 Improved care over the categorization of cases based on disease stage or manifestation of phenotype might help overcome these problems, 27, 28, [36] [37] [38] but only if improved phenotype precision outweighs the loss in power that comes from the consequent reductions in sample size.
Whether genetic variants that alter predisposition to DKD have effects that are specific to DKD, or whether they instead modulate the overall risk of generalized kidney disease remains unclear. Efforts using genomewide association studies (GWAS) directed towards CKD, which typically include cases attributable to a range of pathologies, have been considerably more successful in identifying genetic association than those specifically directed towards DKD. 42 Some genetic associations with CKD, such as variants near UMOD, seem to be detectable irrespective of the primary renal pathology (including DKD). Among African Americans, a genetic variation in APOL1 is reported to be associated with risk of DKD. DKD risk alleles in APOL1 are absent in the European population and appear to have been the target of positive selection in individuals of African descent, likely due to conferred protection against trypanosomal infection. [43] [44] [45] The risk of kidney disease associated with APOL1 variants is larger than the risk associated with any other suspected DKD risk variant, but is independent of diabetes status. 46 Candidate gene studies Before the advent of GWAS, the principal strategy for the identification of DKD risk variants involved candidate gene analysis. Candidate genes were selected based on a priori information regarding their gene products, which were either known or suspected to be involved in the pathogenesis of DKD. In some instances, candidate genes were selected because they mapped to regions implicated through family-based linkage analysis.
This candidate gene approach has proven to be an unreli able guide for the identification of genuine DKD risk variants (as it has for many other disease traits). Most candidate gene studies were conducted in small case-control samples, each of which used different definitions for DKD phenotype. 47 These studies have often adopted insufficiently stringent thresholds for statistical significance, compounded by inadequate correction for multiple testing and the effects of publication bias. 47 On some occasions, data aggregation through meta-analyses has provided more encouraging evidence for association, but in most of these studies the levels of statistical significance for these associations has still fallen well below the thresholds set to ensure robust evidence of association in GWAS. 47 The best-studied and most plausible genetic associations with DKD, such as that involving the insertion/ deletion (I/D) variant in the gene encoding ACE, remain to be fully confirmed. ACE inhibitors have a proven clinical function in protection against DKD through decreasing glomerular hypertension and permeability, and the ACE I/D variant is associated with a twofold increase in ACE activity. 48, 49 Taken together, ACE is a highly credible biological candidate for DKD. Nominal associ ations between the ACE I/D variant and a range of DKD pheno types had been reported in a large number of candidate gene studies. 50 A subsequent meta-analysis that included >26,000 individuals from 63 studies provided additional support for a role of the ACE I/D variant in DKD, with the effect mainly evident among Asian populations with T2DM (OR = 1.28). 50 The evidence for this associ ation, however, remained markedly short of reaching genome-wide significance. 50 Furthermore, this meta-analysis failed to include data from GWAS, thus leaving the findings dominated by a large number of relatively small studies for which the quality of study design and implementation can be difficult to determine. Even for the strongest genetic candidates, the data linking specific sequence variants to DKD phenotypes remain inconclusive.
Genome-wide studies
For many disease traits, the identification of robust and reproducible associations has benefited greatly from GWAS. This approach ( Figure 1 ) has supported systematic screens for common variant associations to traits of interest that require no prior assumptions regarding the biology of the disease. 35 A state-of-the-art GWAS interrogrates >10 million variants across the genome. 51 The requirement to make due allowance for extensive multiple testing has led to the adoption of rigorous thresholds for the declaration of statistical significance and a strong impetus towards replication, both of which have limited false claims of associ ation. 52, 53 GWAS have proven highly effective in identi fying robustly associated loci for numerous complex traits and diseases, such as T2DM and coronary artery disease (CAD). 54, 55 In the case of T2DM, >80 disease regions have been identified to date. 54 The majority of these disease regions map to intergenic loci, Nature Reviews | Nephrology Figure 1 | Schematic of the workflow of genome-wide association studies. These studies can be population-based or designed as case-control studies making up a set of samples. The DNA from these samples is genotyped using SNP array technology. After extensive sample and genotype quality control, the remaining genotypes are used to impute additional genotypes from a reference panel. An association analysis for the trait of interest is then performed and signals for follow-up might be identified. Association of follow-up signals are tested with the same phenotype in a validation sample set that is distinct from the samples used in the original study. Signals that achieve genome-wide significance (P <5 × 10 -8 ) are considered to be robustly associated with the trait of interest. Abbreviation: SNP, single nucleotide polymorphism.
and few of them involve genes previously implicated in disease, an observation that casts further doubt on the value of the candidate gene approach. 54 The first application of GWAS to DKD was published in 2009. 56 This study, which used pooled DNA from 547 patients with T1DM and ESRD and 549 controls with T1D and no evidence of DKD, identified no significant associations. 56 A further study from the GoKinD combined a GWAS of >1,700 individually typed patients with T1DM (820 of whom had DKD) with a replication analysis in 1,304 patients from the DCCT/EDIC trial (Table 1) . 57 Promising associations were identified in the FRMD3 and CARS loci; however, neither signal reached genome-wide significance nor were the results widely replicated. 58 Over the past 5 years, discovery efforts for complex traits have moved towards the development of international consortia to support large-scale meta-analysis of multiple individual GWAS; for some diseases, these efforts include many tens of thousands of cases. 54, 59 This approach has been successful for many diseases and phenotypes, including traits such as schizophrenia and hypertension, for which findings from the initial rounds of single-study GWAS had, as with DKD, appeared unrewarding. The sample size at which the discovery of stat istically significant genome-wide associations begins to increase varies by at least an order of magnitude between traits (Figure 2 ). The reasons behind these differences are poorly described, but probably include between-trait differences in heritability, selective pressure, aetiological heterogeneity and the extent of case-control misclassification. The overall impact of these factors on the outcome of GWAS is difficult to predict in advance for any given trait.
The largest GWAS meta-analysis of DKD published to date involved the 6,691 patients with T1DM assembled by GENIE; variants reaching a P <1 × 10 −5 in the initial GWAS stage were evaluated in a further 5,156 individuals. Two genomic regions were significantly associated with ESRD in a joint analysis, one in AFF3 (P = 1.2 × 10 −9
) and one between RGMA and MCTP2 (P = 2.0 × 10 −9 ). A third signal, within the intronic region of ERBB4, emerged when the case definition was extended to include ESRD or macroalbuminuria (P = 2.1 × 10 −7 ). 60 In a subsequent reanalysis of these data, a further common variant signal mapping near SP3 was significantly associated with ESRD (P = 3.9 × 10 -8 ), specifically among women. 60 All these loci, however, will benefit from confirmation in independent cohorts before they can be universally accepted as genuine DKD risk loci.
The genetics of DKD in T2DM has received less attention than that in T1DM. Several family-based linkage studies have been performed, the largest in the multi-ethnic FIND that analyzed eGFR, renal failure and albuminuria in ~4,000 individuals. [61] [62] [63] Selected chromo somal regions have emerged from these studies with credible evidence for linkage; however, the location of any signal is poorly specified. Identification of causal variants within these linkage signals will almost certainly require large-scale sequence-based exploration of these Two promising approaches currently exist for robust discovery of DKD risk variants. Firstly, the expansion of GWAS in terms of sample size and the scope of the variants interrogated (including more low frequency variants) has been beneficial for many complex traits, and there is no obvious reason as to why this will not be the case for DKD. This rationale underpins the ongoing efforts of SUMMIT and the JDRF-DNCRI, which are compiling a combined GWAS resource of >25,000 participants with diabetes characterized for DKD status (Table 1) .
The second approach relies upon exome or whole genome sequencing of the samples of interest. Sequencebased analyses facilitate the detection and genotyping of alleles of lower frequency than those typically interrogated by GWAS. The expectation is that a subset of these rare alleles will have comparatively large individual effects on DKD risk. Initial efforts in this respect have been on a small scale 65, 66 (typically ~1,000 exomes per study), but the falling costs of sequencing, and access to robust methods for characterizing rare deleterious mutations, 67 offer exciting opportunities for future research.
Diabetic retinopathy
The majority of patients with DKD develop other microvascular complications of diabetes, of which diabetic retinopathy is the most apparent. The prevalence of diabetic retinopathy is twofold higher among patients with comorbid T2DM and microalbumin uria, and sixfold higher among patients with T2M and macroalbuminuria than among diabetic individuals without evidence of renal dysfunction. [68] [69] [70] Although the majority of patients with DKD have diabetic retinopathy, not all of those with diabetic retinopathy will develop DKD. 68 This finding suggests that both shared and complication-specific mechanisms contribute to the different microangiopathic phenotypes.
Diabetic retinopathy is characterized by retinal microvascular changes. Increased vascular permeability and capillary degeneration, resulting in microaneurysms and exudates, is followed by neovascularization in the later proliferative stages. 6 Clinical data support at least two potentially distinct pathological processes that result in proliferative retinopathy and macular oedema, respectively. 71 The predominant clinical risk factors for diabetic retinopathy are duration of diabetes, chronically elevated levels of haemoglobin A 1c , and poor control of blood pressure and lipid levels. 72 Heritability estimates for diabetic retinopathy range from 18% to 52%, which is consistent with a substantial genetic component to susceptibility. [73] [74] [75] The wide range in these estimates reflects the challenges in defining case-control status for such a progressive, continuous and heterogeneous phenotype. These challenges are the same as those facing DKD research, and they have had a similar negative impact on the progress of efforts to identify diabetic retinopathy risk variants.
The majority of genetic discovery work in diabetic retinopathy, as with DKD, has been invested in candidate gene analyses, but few compelling findings have been identified thus far. 76, 77 Two of the best-studied and most biologically credible candidate genes are VEGFA (which encodes a vascular endothelial growth factor already targeted for clinical use in diabetic retino pathy) and AKR1B1 (which encodes aldose reductase, the rate-limiting enzyme in the polyol pathway implicated in glucose-related tissue damage). Variants known to influence VEGF expression, 78, 79 however, show at best only marginal association with diabetic retinopathy [80] [81] [82] and the association data for AKR1B1 are similarly inconclusive. 82, 83 Claims have been made for a contribution to diabetic retinopathy and DKD risk from variants in the promoter of the EPO gene, 84 but these observations have not been successfully replicated. 58 Few GWAS of diabetic retinopathy have been attempted to date. [85] [86] [87] [88] Reanalysis of the GoKinD and EDIC data sets (including 973 cases of diabetic retinopathy and 1,856 controls without diabetic retinopathy, in patients with T1DM) generated no statistically significant or reproducible associations. 76 The most promising approach in the near-term lies, as with DKD, in the much larger sample sizes currently being assembled for GWAS by international consortia, such as SUMMIT. 76 
Diabetic neuropathy
The presentation of diabetic neuropathy is highly vari able, and the mechanisms responsible are hetero geneous. 89 Contributions from both vascular damage (small vessel ischaemia) and metabolic disruption (including glycation Figure 2 | GWAS sample sizes and locus discovery rates for complex traits. The plot summarizes the maximum number of loci reported from GWAS for selected traits, given the effective sample size. For each trait, there is a threshold sample size above which the rate of locus discovery accelerates. Sample sizes for published GWAS for diabetic kidney disease (arrow) remain below these thresholds. Abbreviation: GWAS, genome-wide association study.
end products) seem likely. 89 Although there has been considerable success in the identification of causal genetic mutations for monogenic neuropathic conditions, such as those in SCN9A and TRPA1, 90 few studies of the genetic basis of diabetic neuropathy and other common neuropathic conditions have been conducted. 89 Candidate gene studies have been restricted to small sample sets, and there have been, as yet, no published GWAS. 89, 91 Macrovascular complications CAD, ischaemic stroke and peripheral arterial disease (PAD), are the dominant macrovascular complications among patients with T2DM. 92 Diabetes accelerates the process of atherosclerosis through various mechanisms, for example, hyperglycaemia promotes vascular dysfunction by inhibiting nitric oxide production in endothelial cells and platelets, impairing endotheliumdependent vasodilation and increasing production of ROS. [92] [93] [94] These processes destabilize atherosclerotic plaques and render them vulnerable to rupture, whereas the hyper coagulable state increases the formation and persistence of thrombi. In animal models of diabetes, vascular repair is compromised, which results in an increase and prolongation of ischaemic stroke injury. 95, 96 In contrast to disease in those without diabetes, PAD in patients with diabetes commonly presents below the knee, is more frequently accompanied by medial calcification, and is more likely to have consequences that are compounded by concomitant neuropathy, such as ulceration. 93, 97 The variation in the presentation, severity and pathology of these macrovascular complications raises the question as to whether there is a quantitative or qualitative difference in the pattern of variants influencing the risk of CAD, ischaemic stroke and PAD among individuals with diabetes as compared to those without diabetes. If such heterogeneity exists, there could be important opportunities for targeted management of these conditions. Few studies, however, have been informative in answering this question. Candidate gene studies have been underpowered and intrinsically too narrow in scope to identify diabetes-specific association profiles. The large collaborative GWAS currently being conducted for CAD (and to a lesser degree for ischaemic stroke and PAD) are likely to prove much more fruitful. 55, [98] [99] [100] [101] [102] [103] [104] These studies typically include substantial numbers of participants with diabetes, often ~30% of the total sample, making it possible to perform well-powered studies to compare the allelic effects of single nucleotide polymorph isms (SNPs) on macrovascular disease, stratified by diabetes status.
Preliminary findings obtained by combining data from SUMMIT and CARDIoGRAMplusC4D (Table 1) have provided early evidence that the effects of known variants for CAD at chromosome 9p21 near CDKN2A (Figure 3 ) and at ADAMTS7 showed evidence for interaction with diabetes status. 105 A previous, smaller study in patients with T2DM concluded that the 9p21 signal had a more marked influence on CAD risk among those with poor diabetic control. 106 Another study identified a signal in a separate locus that was associated with CAD and showed evidence of interaction with diabetes status. 107 Intergenic variants between GLUL and ZNF648 have been associated with CAD in patients with T2DM and an interaction with T2DM status has also been reported. 107 One of the strongest signals that influences predisposition to PAD, first identified in samples not stratified for diabetes status, maps near the CHRNA3 locus encoding one of several nicotinic receptors and is thought to act through its impact on smoking behaviour. 102 The same variant is associated with smoking status and quantity. 102 Some evidence suggests that the association between PAD and variants near CHRNA3 is less marked in subjects with diabetes. 105 One interpretation is that the potent direct impact of diabetes on the risk of PAD dilutes the indirect effect of CHRNA3 variants whose effects are mediated by differences in smoking behaviour.
GWAS data allow researchers to address questions related to shared genetic risk, such as whether variants that potentially influence predisposition to T2DM have any detectable effect on risk of CAD. Evidence for overlap between these two conditions might simply reflect the known effects of T2DM on CAD risk, or suggest broader shared pathologies. The most obvious example of overlap lies on chromosome 9p21 where the region near the cyclin dependent kinase inhibitor genes, CDKN2A and CDKN2B, harbours both CAD and T2DM-risk loci. 55, 101, [108] [109] [110] [111] The relationship between these signals is, however, complex; 112 the variants displaying the strongest signals for CAD and T2DM are not correlated and map to distinct subregions separated by active recombination hotspots. By contrast, a second independent regional signal for T2DM (lead SNP, rs944801) exhibits a more direct overlap with the principal CAD signal, 109 and there is some evidence for variants that influence both traits (Figure 3) . 113 
Epigenetics and diabetes complications
Hyperglycaemia is a major risk factor for all diabetic complications but the mechanisms responsible have remained elusive. Candidate mechanistic pathways include protein glycation, increased flux through the polyol pathway, and formation of ROS. The concept of 'metabolic memory' was coined to account for the observation that intensified metabolic control in the years following the diagnosis of T1DM was associated with fewer diabetic complications 20 years later, even in those in whom the improvement in metabolic control had not been maintained. 12, [114] [115] [116] Experimental evidence (reviewed elsewhere 117 ) shows that epigenetic events underlie metabolic memory and contribute to the development of diabetic complications. Covalent marks on histones have a critical role in gene expression and are preserved even after cell division. Changes in activating or inactivating histone marks represent a dynamic epigenetic mechanism by which glucose could influence expression of potentially damaging genes in target tissues. 118, 119 Exposure of cells to high levels of glucose can lead to epigenetic changes that affect the expression of genes and REVIEWS microRNAs even after glucose exposure has returned to normal levels. Epigenetic modifications affect the expression of genes related to the extracellular matrix, TGF-β signalling pathway, and the renin-angiotensin system in glomeruli that have been implicated in the pathogenesis of DKD. 120 Several microRNAs show altered expression in the kidneys of patients with diabetes, and subsequently influence the expression of genes involved in the TGF-β pathway. Changes in TGF-β expression can upregulate the microRNA miR-192, which in turn increases the expression of key fibrotic genes in mesangial cells. 121 Variants in UNC13B, a gene that might regulate hyperglycaemia-induced glomerular apoptosis, have shown modest, but unreplicated, evidence of association with DKD, 122, 123 and there is evidence of hypermethylation of the UNC13B promoter region in epithelial cells isolated from patients with T1DM. 124 Taken together, these (and other) observations 117 support the notion of epigenetic modulation of cellular expression as a common pathway through which both genetic predisposition and environmental perturbation (for example, chronic hyperglycaemia) might interact to define individual risk of DKD.
Future directions
Delays in identifying genetic variants that are robustly associated with differences in individual predisposition to the complications of diabetes, have constrained progress towards a mechanistic understanding of these conditions. Some approaches to overcome these limitations are outlined in Figure 4 .
From the genetic perspective, improved power to detect genetic signals will result from increases in sample size, complete capture of variant diversity, and improved refinement of the phenotypes of interest. Collaborative meta-analyses have proven powerful for delivering robust associations for other complex traits, including those for which early GWAS appeared uninformative, 59, 125, 126 and are now being applied to analyse the genetic basis of complication risk. 60 These efforts will be enhanced by extending genome-wide evaluation to lower frequency variants through sequence-based discovery. Such studies will, at least initially, focus on individuals with extreme phenotypes, such as those without complications despite prolonged T1DM. As well as revealing additional signals, these analyses will improve the prospects for moving from broad regions of association to identification of the specific variants responsible. 54 Opportunities for more detailed phenotypic refinement of complex traits are available. Enlargement of discovery datasets through meta-analyses will make it possible to initiate exploratory analyses to detect signals restricted to particular groups of individuals on the basis of phenotype, age or sex, and to target these patient subsets for follow-up. Such approaches will benefit from investment in cohorts with more informative phenotypes, such as longitudinal data on the progression of complications, and those which are able to take proper account of accumulated exposure to hyperglycaemia and other risk factors. Reference SNPs for CAD are rs1333049 and rs7865618, 133 and for T2DM are rs944801 and rs10811661. 109 Although the signal at rs10811661 is specific to T2DM and rs1333049 is specific to CAD, there is some overlap in the signals represented by rs944801 and rs7865618 for both CAD and T2DM. The long noncoding RNA, CDKN2B-AS1, (also known as ANRIL), maps to the associated region and might be involved in mediating the association effect. 132 Abbreviations: CAD, coronary artery disease; SNP, single nucleotide polymorphism; T2DM, type 2 diabetes mellitus.
Given a set of robust genetic signals, numerous complementary strategies can be used to tease out the functional mechanisms that underlie identified associ ations. These efforts are highly reliant on the development and characterization of appropriate cellular 127 and animal models for diabetic complications [128] [129] [130] that enable the molecular consequences of variant and gene perturbations to be investigated. The relevance of such models to human disease, however, remains a concern, 23 mandating efforts to improve the information available from human studies. Examples of relevant human studies include histological examination of diseased tissues, genomic analyses (for example, transcriptome profiling of renal cell-types) 131 and intensive physiological and molecular phenotyping of individuals of known genotype. Although many of these resources are in place, and others are being generated, substantial fragmentation remains. Experience from other diseases indicates a need for improved coordination of research if we are to define the molecular basis of these traits.
Conclusions
The value of human genetics as a tool for understanding the origins of disease is unquestionable and genomewide approaches to risk-variant discovery are providing novel mechanistic insights for many complex traits. The patterns of discovery for complications associated with diabetes, such as DKD, are expected to follow those observed for other complex traits, and we can expect the accrual of greater sample sizes to lead to a valuable harvest of robustly associated loci. The challenge will be to use associ ation signals to support mechanistic inference and to drive translational advantage. Clinical opportunities will come in several forms. Firstly, human genetics can reveal novel targets for therapeutic intervention-their value for pharmaceuticals is enhanced by evidence that perturbation of function and/or expression in humans has a demonstrable, causal effect on the development of complications. Secondly, human genetics can provide clues to novel biomarkers that enable complication risk and disease progression to be predicted and monitored. The most useful biomarkers will be those that can be shown, by genetic approaches, to lie on the causal pathway toward disease. These biomarkers have the greatest potential for premorbid prediction of the complication risk profile of an individual, and for cataloguing the response to disease-modifying interventions. In addition, robust biomarkers of disease progression will also lower the barrier for pharmaceutical companies to develop and test novel interventions, by adopting trial designs that focus on high-risk individuals and reliable early end points. Figure 4 | Schematic of future directions for characterizing genetic associations with complications of diabetes. Advances in identifying risk variants, and using these to derive mechanistic inferences, will require the integration of multiple data types. Some of these advances focus on refining and improving the genetic signal by increasing the sample dataset, utilising robust and reproducible phenotypes, analysing more variants, and performing additional subset and superset analyses. Other advances focus on providing data that will enable the functional consequences of genetic variants to be explored. Cell, animal, and human studies can be used in concert to improve the functional signal. The combination of genetic and functional data will facilitate understanding of the mechanistic mechanism by which sequence variants contribute to disease risk. Abbreviation: IPSCs, induced pluripotent stem cells.
